Zobrazeno 1 - 10 of 69 pro vyhledávání: '"Konstantinos Tryfonidis"'
1
Akademický článek
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Autor: Florentine S. Hilbers, Coralie Poncet, Konstantinos Tryfonidis, Giuseppe Viale, Suzette Delaloge, Jean-Yves Pierga, Etienne G. C. Brain, Isabel T. Rubio, Alastair M. Thompson, Emiel J. T. Rutgers, Martine J. Piccart, Laura J. van ’t Veer, Fatima Cardoso
Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Small, hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative breast cancers are associated with relatively low rates of disease recurrence and have therefore been underrepresented in clinical trials assessing the effect
Externí odkaz: https://doaj.org/article/d632b4b675464734a9b0c41dc7dee912
Zobrazit plný text záznamu
2
Akademický článek
From bench to clinical trials the EORTC experience in biology-based clinical cancer research
Autor: Konstantinos Tryfonidis, Katherine Hartmann, Marie Morfouace, Denis Lacombe
Publikováno v: Journal of the Egyptian National Cancer Institute, Vol 29, Iss 4, Pp 171-176 (2017)
For over 50 years the European Organization for Research and Treatment of Cancer (EORTC) has delivered major advances in cancer clinical research and cancer therapeutics. The introduction of molecularly targeted agents has led to significant improvem
Externí odkaz: https://doaj.org/article/4a83b7e4742247278ee7beeebdf9efb4
Zobrazit plný text záznamu
3
Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
Autor: Erika Hamilton, Junji Tsurutani, Giuseppe Curigliano, Miguel Martín, Ciara C. O’Sullivan, Joo Hyuk Sohn, Konstantinos Tryfonidis, Libero Santarpia, Shan Yang, Véronique Diéras
Publikováno v: Cancer Research. 83:OT2-16
Background: The current first-line (1L) standard of care (SOC) for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is trastuzumab (T) plus pertuzumab (P) and a taxane. Despite advances in 1L SOC, most patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e58490b680a4adb85b002991bf7c785
https://doi.org/10.1158/1538-7445.sabcs22-ot2-16-03
Zobrazit plný text záznamu
4
Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
Autor: Erika Hamilton, Junji Tsurutani, Joohyuk Sohn, Giuseppe Curigliano, Ciara C. O’Sullivan, Miguel Martín, Konstantinos Tryfonidis, Libero Santarpia, Shan Yang, Veronique Dieras
Publikováno v: Cancer Research. 83:CT065-CT065
Background: The current first-line (1L) standard of care (SOC) for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is trastuzumab (T) plus pertuzumab (P) and a taxane. Despite advances in 1L SOC, most patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc2ffcd3f851990a5468e0426099a548
https://doi.org/10.1158/1538-7445.am2023-ct065
Zobrazit plný text záznamu
6
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Autor: Joohyuk Sohn, S.-B. Kim, Konstantinos Tryfonidis, A. Wang, Peter Schmid, Eva Muñoz-Couselo, Lina Yin, Roberto Salgado, Rebecca Dent, Sherene Loi, S-A. Im, Vassiliki Karantza, J. Cortes, Sherko Kuemmel, Theodoros Foukakis, Younghee Park
Publikováno v: Annals of Oncology. 31:569-581
Background The phase Ib KEYNOTE-173 study was conducted to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy plus pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC). Patients an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60401138d0964dc85f5fec0e7e7051f4
https://doi.org/10.1016/j.annonc.2020.01.072
Zobrazit plný text záznamu
8
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG/ BIG5–13/TESARO PR-30–50–10-C BRAVO Study
Autor: Gabriele Zoppoli, William Audeh, Theodora Goulioti, David Cameron, Iain R. Macpherson, Marco Colleoni, Antonino Musolino, Luis Manso, Audrey Mailliez, Evangelia Razis, Andrew Tutt, Virginie Adam, Peter Vuylsteke, John K. Erban, Michail Ignatiadis, Kai Yu Jen, István Láng, Bella Kaufman, Aafke H. Honkoop, Konstantinos Tryfonidis, Saskia Litière, Oskar T. Johannsson, Judith Balmaña, Olivier Tredan, Susan Ellard, Nicholas C. Turner, María José Juan-Fita, Lori J. Goldstein, C. Poncet
Publikováno v: Clinical cancer research, 27 (20
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative adva
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a1bfde4ac52e52c38e495f34c523cc
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje